Derivative spectrophotometry method for simultaneous estimation of rupatadine and montelukast in their combined dosage form

Pg, Patel; Vm, Vaghela; Sg, Rathi; Nb, Rajgor; Bhaskar, V. H.

doi:10.4103/0975-1483.59327

Cited by 14 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Literature survey reveals that few analytical methods are available for the simultaneous estimation of MON and DES in pharmaceutical formulations by using UV [9]- [11] and HPLC [12]- [15]. Hence, we made an attempt to develop a simple method for the simultaneous estimation of MON and DES by RP-HPLC in pharmaceutical dosage forms.…”

Section: Introduction Montelukast Sodium (Mon) (Figure 1) Is Chemicalmentioning

confidence: 99%

Method Development and Validation for Simultaneous Estimation of Montelukast Sodium and Desloratadine by RP-HPLC

Bonthu¹,

Rao²,

Rao³

2015

AJAC

View full text Add to dashboard Cite

A novel, precise, accurate, rapid and cost effective isocratic reverse-phase high performance liquid chromatographic (RP-HPLC) method was developed, optimized and validated for the simultaneous estimation of Montelukast Sodium (MON) and Desloratadine (DES) in pharmaceutical dosage forms. The drugs were estimated using Hypersil BDS C18 (250 mm × 4.6 mm I.D., 5 μ particle size) column. The mobile phase composed of orthophosphoric acid and water in the ratio of 20:80 v/v, at a flow rate of 1.0 ml/min was used for the separation. Detection was carried out at 280 nm. The linearity range obtained was 10 -30 µg/ml for MON and 5 -15 µg/ml for DES with retention times of 2.929 min and 4.439 min for MON and DES respectively. The correlation coefficient values were found to be 0.999. Precision studies showed % RSD values less than 2% for both the drugs in all the selected concentrations. The percentage recoveries of MON and DES were in the range of 99.59% -99.82% and 99.60% -99.80% respectively. The limit of detection (LOD) and limit of quantification (LOQ) were 0.176 µg/ml, 0.587 µg/ml for MON and 0.087 µg/ml, 0.292 µg/ml for DES respectively. The method was validated as per the International Conference on Harmonization (ICH) guidelines. The proposed validated method was successfully used for the quantitative analysis of commercially available tablet dosage forms.

show abstract

Section: Introduction Montelukast Sodium (Mon) (Figure 1) Is Chemicalmentioning

confidence: 99%

Method Development and Validation for Simultaneous Estimation of Montelukast Sodium and Desloratadine by RP-HPLC

Bonthu¹,

Rao²,

Rao³

2015

AJAC

View full text Add to dashboard Cite

show abstract

“…The literature pointed to some reports for RUP estimation like densitometric [5], derivative UV spectrophotometry [6,7], RP-HPLC [8][9][10][11], GC-MS [12,13] voltametric techniques [14], RP-UPLC [15], LC-MS/MC [16], capillary zone electrophoresis [17], HPTLC [18], non-aqueous potentiometric titration method [19] and spectrofluorometric derivatization technique [20]. Different analytical methods have been used in determination of MKT such as RP-HPLC [21,22], UV spectrophotometry [23], spectrofluorometric [24], derivative spectrofluorometry [25] and voltametric technique [26].…”

Section: Introductionmentioning

confidence: 99%

Green quantitative spectrofluorometric analysis of rupatadine and montelukast at nanogram scale using direct and synchronous techniques

et al. 2021

View full text Add to dashboard Cite

Two green-sensitive spectrofluorometric methods were investigated for assay of rupatadine (RUP) [method I] and its binary mixture with montelukast (MKT) [method II]. Method I depends on measuring native fluorescence of RUP in the presence of 0.10 M H 2 SO 4 and 0.10%w/v sodium dodecyl sulfate at 455 nm after excitation at 277 nm. The range of the first method was 0.20–2.00 µg ml −1 with detection and quantitation limits of 59.00 and 179.00 ng ml −1 , respectively. Method II depends on the first derivative synchronous spectrofluorometry. The derivative intensities were measured for the two drugs in an aqueous solution containing Mcllvaine's buffer pH 2.60 at fixed Δ λ of 140 nm. Each drug was estimated at zero-contribution of the other. The intensity was measured at 261 and 371 nm for RUP and MKT, respectively. The method was linear over 0.10–4.00 and 0.20–1.60 µg ml −1 with limits of detection 31.00 and 66.00 ng ml −1 and limits of quantitation 94.00 and 200.00 ng ml −1 for RUP and MKT, respectively. The method was extended to determine this mixture in laboratory-prepared mixtures and combined tablets. Method validation was performed according to ICH guidelines. Statistical interpretation of data revealed good agreement with the comparison method. Method greenness was confirmed by applying three different assessment tools.

show abstract

“…[ 6,7 ] Few spectrophotometric methods have been reported for determination of RPT in pharmaceutical tablets. [ 8–12 ] Conversely, several chromatographic methods with various detection patterns have been reported to determine rupatadine. [ 13–24 ] Chromatographic techniques require large volumes of hazardous organic solvents, tedious procedures, sometimes need expensive detectors and have lengthy procedures.…”

Section: Introductionmentioning

confidence: 99%

Resonance Rayleigh scattering and spectrofluorimetric approaches for the selective determination of rupatadine using erythrosin B as a probe: application to content uniformity test

et al. 2020

View full text Add to dashboard Cite

In this study, spectrofluorimetric and resonance Rayleigh scattering techniques were applied for the first time for determination of rupatadine through two validated methods. The proposed methods were based on a facile association complex formation between rupatadine and erythrosin B reagent in acidic medium. Spectrofluorimetric determination relied on the quenching effect of rupatadine on the fluorescence intensity of erythrosin B at 556 nm (excitation = 530 nm). Conversely, the resonance Rayleigh scattering (RRS) method relied on enhancement in the resonance Rayleigh scattering spectrum of erythrosin B at 344 nm after the addition of rupatadine. The developed methods produced linear results over ranges 0.15−2.0 μg/ml and 0.1−1.5 μg/ml, with detection limits of 0.030 μg/ml and 0.018 μg/ml for the spectrofluorimetric method and the RRS method, respectively. All reaction conditions for rupatadine–erythrosin B formation were optimized experimentally and both methods were validated according to International Council for Harmonisation guidelines. The developed methods were applied to estimate rupatadine content in its pharmaceutical tablet dosage form with acceptable recoveries. Furthermore, a content uniformity test for the commercial rupatadine tablets was successfully applied by the suggested spectroscopic methods according to United States Pharmacopeia guidelines.

show abstract

Derivative spectrophotometry method for simultaneous estimation of rupatadine and montelukast in their combined dosage form

Cited by 14 publications

References 13 publications

Method Development and Validation for Simultaneous Estimation of Montelukast Sodium and Desloratadine by RP-HPLC

Method Development and Validation for Simultaneous Estimation of Montelukast Sodium and Desloratadine by RP-HPLC

Green quantitative spectrofluorometric analysis of rupatadine and montelukast at nanogram scale using direct and synchronous techniques

Resonance Rayleigh scattering and spectrofluorimetric approaches for the selective determination of rupatadine using erythrosin B as a probe: application to content uniformity test

Contact Info

Product

Resources

About